FDA Accelerates Review of Pancreatic Cancer Drug Darazonlasib
Dr. Janet Nesheiwat, a family and emergency physician, discussed on “Fox Report” how artificial intelligence could play a role in detecting pancreatic cancer sooner and in aiding the FDA’s expedited review of the drug Darazonlasib.
A recent report suggests that streamlining the Food and Drug Administration’s (FDA) review process could create trillions in economic benefits and provide quicker access to crucial treatments for patients. Thomas Phillipson, an economist and former acting chairman of the White House Council of Economic Advisers, remarked in an interview that the FDA process typically takes around ten years to complete. Interestingly, most of that time isn’t primarily focused on safety assessments; rather, it’s centered on efficacy testing.
The report, titled “A Multitrillion-Dollar Opportunity for FDA Reform,” estimates that reducing the FDA’s efficacy review time by just one year could yield over $10 trillion in economic value by hastening the introduction of new treatments and spurring further medical innovation.
The document also pointed out that 19 drug approvals are expected to have a “significant clinical impact” in 2024, according to GOODRX.
Furthermore, Phillipson emphasized that delays in drug approvals generally arise from efficacy determinations rather than safety concerns. He stated, “Although the FDA has a congressional mandate to enhance both safety and effectiveness, the unique role it plays in ensuring efficacy is often overlooked.” He argued that accelerating the approval process might foster competition among pharmaceutical manufacturers, ultimately leading to reduced prescription drug costs.
Phillipson also mentioned that faster approvals could significantly improve drug availability for patients as it would boost competition among drugs released sooner.
The report critically examines whether the federal government’s considerable role in assessing drug effectiveness before market entry should continue. It suggests that speeding up approvals by one to six years could allow for trillions in economic value through quicker access to drugs and increased innovation incentives. However, it also raises concerns that China’s faster and less expensive clinical trial procedures could attract investment and drug development away from the U.S.
In light of this competitive challenge from China, Phillipson urged policymakers to rethink the pace of FDA approvals. He noted, “This is where the president’s role is essential in promoting efforts similar to what we achieved with Operation Warp Speed during the COVID-19 pandemic. It’s just as urgent for those suffering from a range of other diseases.”
The authors of the report advocate for reforms like incorporating more artificial intelligence in drug evaluations, designing faster clinical trials, and expanding “right-to-try” programs for patients.
